[1] Vilella AJ, Severin J, UretaVidal A, et al. EnsemblCompara gene trees: complete, duplicationaware phylogenetic trees in vertebrates[J]. Genome Res, 2009, 19(2): 327-335. DOI:10.1101/gr.073585.107.
[2] Zebisch M, Xu Y, Krastev C, et al. Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist Rspondin[J]. Nat Commun, 2013, 4(16): 458464. DOI:10.1038/ncomms3787.
[3] De Lau WB, Snel B, Clevers HC. The Rspondin protein family[J]. Genome Biol, 2012, 13(3): 242. DOI:10.1186/gb-2012-13-3-242.
[4] Clevers H, Nusse R. Wnt/βCatenin signaling and disease[J]. Cell, 2012, 149(6): 1192-1205. DOI:10.1016/j.cell.2012.05.012.
[5] Hao HX, Xie Y, Zhang Y, et al. ZNRF3 promotes Wnt receptor turnover in an Rspondinsensitive manner[J]. Nature, 2012, 485(7397): 195200. DOI:10.1038/nature11019.
[6] Koo BK, Spit M, Jordens I, et al. Tumour suppressor RNF43 is a stemcell E3 ligase that induces endocytosis of Wnt receptors[J]. Nature, 2012, 488(7413): 665-669. DOI:10.1038/nature11308.
[7] Moffat LL, Robinson RE, Bakoulis AA. The conserved transmembrane RING finger protein PLR1 downregulates Wnt signaling by reducing Frizzled, Ror and Ryk cellsurface levels in Celegans[J]. Development, 2014, 141(3): 617-628. DOI:10.1242/dev.101600.
[8] Moad H, Pioszak AA. Reconstitution of Rspondin: LGR4: ZNRF3 adult stem cell growth factor signaling complexes with recombinant proteins produced in Escherichia coli[J]. Biochemistry, 2013, 52(41): 72957304. DOI:10.1021/bi401090h.
[9] Chen PH, Chen XY, Lin ZH, et al. The structural basis of Rspondin recognition by LGR5 and RNF43[J]. Genes Dev, 2013, 27(12): 1345-1350. DOI:10.1101/gad.219915.113.
[10] Peng WC, de Lau W, Madoori PK, et al. Structures of Wntantagonist ZNRF3 and its complex with Rspondin 1 and implications for signaling[J]. PLoS One, 2013, 8(12): e83110. DOI:10.1371/journal.pone.0083110.
[11] Xie Y, Zamponi R, Charlat O, et al. Interaction with both ZNRF3 and LGR4 is required for the signalling activity of R-spondin[J]. EMBO Rep, 2013, 14(12): 1120-1126. DOI:10.1038/embor.2013.167.
[12] Takahashi N, Yamaguchi K, Ikenoue T, et al. Identification of two Wntresponsive elements in the intron of RING finger protein 43 (RNF43) gene[J]. PLoS One, 2014, 9(1): e86582. DOI:10.1371/journal.pone.0086582.
[13] Krausova M, Korinek V. Wnt signaling in adult intestinal stem cells and cancer[J]. Cell Signal, 2014, 26(3): 570-579. DOI:10.1016/j.cellsig.2013.11.032.
[14] Shinada K, Tsukiyama T, Sho T, et al. RNF43 interacts with NEDL1 and regulates p53mediated transcription[J]. Biochem Biophys Res Commun, 2011, 404(1): 143-147. DOI:10.1016/j.bbrc.2010.11.082.
[15] Giannakis M, Hodis E, Jasmine Mu X, et al. RNF43 is frequently mutated in colorectal and endometrial cancers[J]. Nat Genet, 2014, 46(12): 1264-1266. DOI:10.1038/ng.3127.
[16] Wang K, Yuen ST, Xu J, et al. Wholegenome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer[J]. Nat Genet, 2014, 46(6): 573-582. DOI:10.1038/ng.2983.
[17] Okuno K, Sugiura F, Hidai JI, et al. Phase Ⅰ clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer[J]. Exp Ther Med, 2011, 2(1): 73-79. DOI:10.3892/etm.2010.182.
[18] Inoue K, Sugiura F, Kogita A, et al. Clinical trial of a sevenpeptide vaccine and tegafururacil/leucovorin as combination therapy for advanced colorectal cancer[J]. Gan To Kagaku Ryoho, 2014, 41(10): 12761279.
[19] Sugiura F, Inoue K, Kogita A, et al. Treatment outcome of peptide vaccination for advanced colorectal cancer[J]. Gan To Kagaku Ryoho, 2013, 40(12): 1584-1586.
[20] Matsushita N, Aruga A, Inoue Y, et al. Phase Ⅰ clinical trial of a peptide vaccine combined with tegafururacil plus leucovorin for treatment of advanced or recurrent colorectal cancer[J]. Oncol Rep, 2013, 29(3): 951-959. DOI:10.3892/or.2013.2231.
[21] Hijikata Y, MurahashiIga M, Okazaki T, et al. Development of novel immune therapies for solid tumors: phase Ⅰ clinical trials in a single institute[J]. Rinsho Ketsueki, 2012, 53(5): 487-492.
[22] Wu J, Jiao Y, Dal Molin M, et al. Wholeexome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitindependent pathways[J]. Proc Natl Acad Sci USA, 2011, 108(52): 21188-21193. DOI:10.1073/pnas.1118046108.
[23] Sakamoto H, Kuboki Y, Hatori T, et al. Clinicopathological significance of somatic RNF43 mutation and aberrant expression of ring finger protein 43 in intraductal papillary mucinous neoplasms of the pancreas[J]. Mod Pathol, 2015, 28(2): 261-267. DOI:10.1038/modpathol.2014.98.
[24] Reid MD, Choi H, Balci S, et al. Serous cystic neoplasms of the pancreas: clinicopathologic and molecular characteristics[J]. Semin Diagn Pathol, 2014, 31(6): 475-483. DOI:10.1053/j.semdp.2014.08.009.
[25] Gala MK, Mizukami Y, Le LP, et al. Germline mutations in oncogeneinduced senescence pathways are associated with multiple sessile serrated adenomas[J]. Gastroenterology, 2014, 146(2): 520529. DOI:10.1053/j.gastro.2013.10.045.
[26] Xing C, Zhou W, Ding S, et al. Reversing effect of ring finger protein 43 inhibition on malignant phenotypes of human hepatocellular carcinoma[J]. Mol Cancer Ther, 2013, 12(1): 94-103. DOI:10.1158/1535-7163.MCT-12-0672.
[27] Ong CK, Subimerb C, Pairojkul CA, et al. Exome sequencing of liver flukeassociated cholangiocarcinoma[J]. Nat Genet, 2012, 44(6): 690-1113. DOI:10.1038/ng.2273.
[28] Jiang X, Hao HX, Growney JD, et al. Inactivating mutations of RNF43 confer Wnt dependency in pancreatic ductal adenocarcinoma[J]. Proc Natl Acad Sci USA, 2013, 110(31): 12649-12654. DOI:10.1073/pnas.1307218110. |